Disease Diagnosis TRIZ Cases

LC-MS/MS detection of digested NT-proBNP peptides resolves immunoassay variability caused by glycosylation heterogeneity.

Immunoassay detects fecal IgA anti-toxin B antibody levels to identify patients at risk of Clostridium difficile infection recurrence.

Combining five protein markers with free PSA ratios reduces false-positive rates by 60% while maintaining 90% sensitivity.

Integrates cellular mass measurements with transcriptome analysis to predict acute lymphoblastic leukemia relapse risk.

Mutated PltA and CdtB toxins act as immunogens to induce protective immune responses, addressing the lack of effective vaccines for young children.

Analyze cell surface receptor clustering patterns to classify tumor responsiveness, enabling precise patient stratification for targeted cancer therapies.

A diagnostic kit quantifies tryptophan, serotonin, and GABA in stool extracts to identify gut-brain axis imbalances.

Merging CT-proET-1 and NT-proBNP detection overcomes low sensitivity of single markers, enabling precise risk stratification for acute coronary syndrome.

Aptamer-based biomarker panel detects impaired glucose tolerance through specific protein signatures, bypassing fasting requirements of oral glucose tests.

Human interleukin-8 improves engraftment rates of primary tumor cells in xenograft models, preserving subclonal complexity for drug screening.

Fluorescent lateral flow strips measure salivary biomarkers to replace complex DEXA systems, enabling accessible early osteoporosis screening.

Detecting P2X4 receptor protein expression levels in patient-derived cancer samples identifies sensitive tumors and predicts therapeutic response.

A polyfunctional T cell assay measures CD107a, IFN-gamma, IL-2, and TNF-alpha expression to predict cytomegalovirus infection risk in transplant recipients.

Combining NGAL with HBP, AST, ALT, bilirubin, ESM-1, and BNP-type peptides improves diagnostic accuracy over single markers.

Serum 2-Cys-PRDX biomarkers replace invasive kidney biopsies to diagnose lupus nephritis and differentiate it from IgA nephropathy with high sensitivity.

Electron spin resonance spectroscopy combined with logistic regression identifies malignancies with 80 to 90 percent sensitivity.

In vitro diagnostic method measuring serum kynurenine concentration to identify patients at risk for contrast-induced nephropathy.

HLA genotype testing combined with testosterone therapy blocks MHC-mediated immune responses to prevent tissue destruction from metal implants.

Plasmapheresis removes anti-endothelin-receptor antibodies from blood to lower titers for treating graft rejection and pre-eclampsia.

A lateral-flow medical device detects proliferative diabetic retinopathy using lacrimal fluid samples and colored microbeads.

Analyzing 349 blood biomarkers across three time phases to identify patients at risk of severe COVID-19 progression.

Synthetic antibodies target unique neoepitopes to isolate circulating tumor cells, resolving toxicity risks from off-target normal cell binding.

Combining PlGF and Activin A biomarkers to detect early-onset preeclampsia, overcoming low sensitivity of traditional screening methods.

Preventing erroneous UCH-L1 increases from preanalytical errors by applying protease inhibitors during collection.

Measuring creatine riboside and cortisol sulfate levels in urine samples replaces radiation-heavy CT scans to improve early-stage diagnostic accuracy.

A multianalyte panel assay measures specific biomarkers in blood serum to predict and diagnose ovarian cancer.

Molecular imprinting creates complementary cavities in a polymer film, replacing costly antibody preparation while maintaining high detection accuracy.

S100B protein measurement identifies brain injury risks without invasive scalp procedures or false positives from fetal heart monitoring.

Correcting biomarker concentrations with an intermediary marker resolves sample volume variations that distort non-invasive diagnostic readings.

Analyzes HER2 and SIAH2 markers to match invasive breast cancer patients with appropriate therapies.

Antigen titration plots specific binding curves to identify true positives independent of absolute antibody amounts.

Segmenting probe densities across multiple sites extends the dynamic range, resolving the trade-off between sensitivity and saturation limits.

Modified cardiac glycosides cross the blood-brain barrier to treat neurological conditions while reducing toxicity risks associated with standard therapies.

A breast cancer detection kit utilizing exosomal TβRII protein in peripheral blood samples.

Monoclonal antibody 1E8.33 detects proCOL11A1 protein expression in stromal cells to identify high-risk breast papillary lesions.

Measuring periostin protein concentration in blood or nasal secretions using an immunoassay to diagnose chronic sinusitis without invasive procedures.

Specific antibodies bind to canine proBNP regions 20-86, replacing complex physical exams with a cost-effective immunoassay for early heart disease diagnosis.

In silico simulation of clotting dynamics assesses thrombin generation parameters to identify high-risk individuals for targeted anticoagulant therapy.

Measuring endocan concentration in blood samples between 3 and 30 hours after surgery detects postoperative pulmonary infections.

Smartphone camera captures conjunctival microcirculation images alongside blood biomarkers to replace complex imaging systems requiring operator expertise.

Second derivative FTIR analysis at 900 to 1200 cm⁻¹ resolves alginate oligomer signals from complex body fluid matrices.

Specific biomarker quantification resolves early identification bottlenecks by enabling precise risk assessment for anxiety and stress disorders.

Multi-marker autoantibody assay reduces mammography false negatives by identifying specific protein binding profiles in bodily fluids.

Screening cancer using protein-free glycosaminoglycan profiles avoids invasive procedures while maintaining high diagnostic accuracy.

Measuring SIGLEC-14, BCAM, and ANGPTL3 resolves the contradiction between diagnostic simplicity and timely intervention for neonatal chronic lung disease.

Photooxidation amplifies weak enzyme signals to quantify trace neurodegenerative proteins, resolving low sensitivity limits of conventional immunoassays.

A method normalizing patient preparation and sample collection to generate a Functional Anorexigenic Signal finding from multiple biochemical indicators.

A hydrazine-functionalized fluorophore reacts with carbonylated biomolecules to form hydrazones, enabling direct fluorescence visualization in live cells.

A diagnostic method using CPS-1 and glutamate levels in blood samples to assess liver fibrosis stages.

A polypeptide immunoassay detects high-affinity antibodies against platelet factor 4 in patient samples.